サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1121394

世界の骨髄異形成症候群（MDS）治療市場：考察と予測 (2028年まで)

Global Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 124 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
世界の骨髄異形成症候群（MDS）治療市場：考察と予測 (2028年まで)
出版日: 2022年09月02日
発行: QYResearch
ページ情報: 英文 124 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、骨髄異形成症候群（MDS）治療 (Myelodysplastic Syndrome (MDS) Treatment) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 骨髄異形成症候群（MDS）治療の製品概要
  • 市場：タイプ別
    • 世界の骨髄異形成症候群（MDS）治療の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Azacitidine
    • Lenalidomide
    • Decitabine
    • Deferasirox
  • 市場：アプリケーション別
    • 世界の骨髄異形成症候群（MDS）治療の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Refractory Cytopenia with Unilineage Dysplasia
    • Refractory Anemia with Ringed Sideroblasts
    • Others
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の骨髄異形成症候群（MDS）治療の販売 推定および予測 2017-2028
  • 世界の骨髄異形成症候群（MDS）治療の収益 推定および予測 2017-2028
  • 世界の骨髄異形成症候群（MDS）治療の収益：地域別: 2017 VS 2021 VS 2028
  • 世界の骨髄異形成症候群（MDS）治療の販売：地域別
    • 世界の骨髄異形成症候群（MDS）治療の販売：地域別 (2017-2022)
    • 世界の販売 骨髄異形成症候群（MDS）治療 ：地域別 (2023-2028)
  • 世界の骨髄異形成症候群（MDS）治療の収益：地域別
    • 世界の骨髄異形成症候群（MDS）治療の収益：地域別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の収益：地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合：メーカー別

  • 世界の骨髄異形成症候群（MDS）治療の販売：メーカー別
    • 世界の骨髄異形成症候群（MDS）治療の上位メーカー：販売別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の販売市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー： 骨髄異形成症候群（MDS）治療2021
  • 世界の骨髄異形成症候群（MDS）治療の収益：メーカー別
    • 世界の骨髄異形成症候群（MDS）治療の収益：メーカー別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の収益市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5企業： 骨髄異形成症候群（MDS）治療の収益 2021
  • 世界の骨髄異形成症候群（MDS）治療の販売価格：メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界の骨髄異形成症候群（MDS）治療の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界の骨髄異形成症候群（MDS）治療のメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の骨髄異形成症候群（MDS）治療の販売：タイプ別
    • 世界の骨髄異形成症候群（MDS）治療の販売実績：タイプ別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の販売予測：タイプ別 (2023-2028)
    • 世界の骨髄異形成症候群（MDS）治療の販売市場シェア：タイプ別 (2017-2028)
  • 世界の骨髄異形成症候群（MDS）治療の収益：タイプ別
    • 世界の骨髄異形成症候群（MDS）治療の収益実績：タイプ別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の収益予測：タイプ別 (2023-2028)
    • 世界の骨髄異形成症候群（MDS）治療の収益市場シェア：タイプ別 (2017-2028)
  • 世界の骨髄異形成症候群（MDS）治療の価格：タイプ別
    • 世界の骨髄異形成症候群（MDS）治療の価格：タイプ別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の価格予測：タイプ別 (2023-2028)

第5章 市場規模：アプリケーション別

  • 世界の骨髄異形成症候群（MDS）治療の販売：アプリケーション別
    • 世界の骨髄異形成症候群（MDS）治療の販売実績：アプリケーション別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の販売予測：アプリケーション別 (2023-2028)
    • 世界の骨髄異形成症候群（MDS）治療の販売市場シェア：アプリケーション別 (2017-2028)
  • 世界の骨髄異形成症候群（MDS）治療の収益：アプリケーション別
    • 世界の骨髄異形成症候群（MDS）治療の収益実績：アプリケーション別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の収益予測：アプリケーション別 (2023-2028)
    • 世界の骨髄異形成症候群（MDS）治療の収益市場シェア：アプリケーション別 (2017-2028)
  • 世界の骨髄異形成症候群（MDS）治療の価格：アプリケーション別
    • 世界の骨髄異形成症候群（MDS）治療の価格：アプリケーション別 (2017-2022)
    • 世界の骨髄異形成症候群（MDS）治療の価格予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米の骨髄異形成症候群（MDS）治療 市場規模：タイプ別
    • 北米の骨髄異形成症候群（MDS）治療の販売：タイプ別 (2017-2028)
    • 北米の骨髄異形成症候群（MDS）治療の収益：タイプ別 (2017-2028)
  • 北米の骨髄異形成症候群（MDS）治療 市場規模：アプリケーション別
    • 北米の骨髄異形成症候群（MDS）治療の販売：アプリケーション別 (2017-2028)
    • 北米の骨髄異形成症候群（MDS）治療の収益：アプリケーション別 (2017-2028)
  • 北米の骨髄異形成症候群（MDS）治療 市場規模：国別
    • 北米の骨髄異形成症候群（MDS）治療の販売：国別 (2017-2028)
    • 北米の骨髄異形成症候群（MDS）治療の収益：国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の骨髄異形成症候群（MDS）治療 市場規模：タイプ別
    • 欧州の骨髄異形成症候群（MDS）治療の販売：タイプ別 (2017-2028)
    • 欧州の骨髄異形成症候群（MDS）治療の収益：タイプ別 (2017-2028)
  • 欧州の骨髄異形成症候群（MDS）治療 市場規模：アプリケーション別
    • 欧州の骨髄異形成症候群（MDS）治療の販売：アプリケーション別 (2017-2028)
    • 欧州の骨髄異形成症候群（MDS）治療の収益：アプリケーション別 (2017-2028)
  • 欧州の骨髄異形成症候群（MDS）治療 市場規模：国別
    • 欧州の骨髄異形成症候群（MDS）治療の販売：国別 (2017-2028)
    • 欧州の骨髄異形成症候群（MDS）治療の収益：国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋の骨髄異形成症候群（MDS）治療 市場規模：タイプ別
    • アジア太平洋の骨髄異形成症候群（MDS）治療の販売：タイプ別 (2017-2028)
    • アジア太平洋の骨髄異形成症候群（MDS）治療の収益：タイプ別 (2017-2028)
  • アジア太平洋の骨髄異形成症候群（MDS）治療 市場規模：アプリケーション別
    • アジア太平洋の骨髄異形成症候群（MDS）治療の販売：アプリケーション別 (2017-2028)
    • アジア太平洋の骨髄異形成症候群（MDS）治療の収益：アプリケーション別 (2017-2028)
  • アジア太平洋の骨髄異形成症候群（MDS）治療 市場規模：地域別
    • アジア太平洋の骨髄異形成症候群（MDS）治療の販売：地域別 (2017-2028)
    • アジア太平洋の骨髄異形成症候群（MDS）治療の収益：地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 台湾
    • インドネシア
    • タイ
    • マレーシア
    • フィリピン

第9章 ラテンアメリカ

  • ラテンアメリカの骨髄異形成症候群（MDS）治療 市場規模：タイプ別
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の販売：タイプ別 (2017-2028)
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の収益：タイプ別 (2017-2028)
  • ラテンアメリカの骨髄異形成症候群（MDS）治療 市場規模：アプリケーション別
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の販売：アプリケーション別 (2017-2028)
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の収益：アプリケーション別 (2017-2028)
  • ラテンアメリカの骨髄異形成症候群（MDS）治療 市場規模：国別
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の販売：国別 (2017-2028)
    • ラテンアメリカの骨髄異形成症候群（MDS）治療の収益：国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカの骨髄異形成症候群（MDS）治療 市場規模：タイプ別
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の販売：タイプ別 (2017-2028)
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の収益：タイプ別 (2017-2028)
  • 中東・アフリカの骨髄異形成症候群（MDS）治療 市場規模：アプリケーション別
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の販売：アプリケーション別 (2017-2028)
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の収益：アプリケーション別 (2017-2028)
  • 中東・アフリカの骨髄異形成症候群（MDS）治療 市場規模：国別
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の販売：国別 (2017-2028)
    • 中東・アフリカの骨髄異形成症候群（MDS）治療の収益：国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • Novartis AG
  • Celgene Corporation
  • Otsuka Pharmaceutical Co., Ltd
  • Sandoz Inc
  • Dr Reddys Laboratories Limited
  • Pharmascience Inc
  • Accord Healthcare Ltd
  • Mylan N.V.

第12章 業界チェーンと販売チャネルの分析

  • 骨髄異形成症候群（MDS）治療 業界チェーン分析
  • 骨髄異形成症候群（MDS）治療 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • 骨髄異形成症候群（MDS）治療 生産形態とプロセス
  • 骨髄異形成症候群（MDS）治療 販売およびマーケティング
    • 骨髄異形成症候群（MDS）治療 販売チャネル
    • 骨髄異形成症候群（MDS）治療 卸業者
  • 骨髄異形成症候群（MDS）治療 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • 骨髄異形成症候群（MDS）治療 業界動向
  • 骨髄異形成症候群（MDS）治療 市場の促進要因
  • 骨髄異形成症候群（MDS）治療 市場の課題
  • 骨髄異形成症候群（MDS）治療 市場の抑制要因

第14章 世界の骨髄異形成症候群（MDS）治療の主な市場調査結果

第15章 付録

図表
  • Table 1. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Azacitidine
  • Table 3. Major Manufacturers of Lenalidomide
  • Table 4. Major Manufacturers of Decitabine
  • Table 5. Major Manufacturers of Deferasirox
  • Table 6. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 7. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 8. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2017-2022) & (K Units)
  • Table 9. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2017-2022)
  • Table 10. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2023-2028) & (K Units)
  • Table 11. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2023-2028)
  • Table 12. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2017-2022) & (US$ Million)
  • Table 13. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2017-2022)
  • Table 14. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2023-2028) & (US$ Million)
  • Table 15. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2023-2028)
  • Table 16. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2017-2022) & (K Units)
  • Table 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Manufacturers (2017-2022)
  • Table 18. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 19. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2017-2022)
  • Table 20. Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturers (2017-2022) &(USD/Unit)
  • Table 21. Global Myelodysplastic Syndrome (MDS) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 22. Global Myelodysplastic Syndrome (MDS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Treatment as of 2021)
  • Table 23. Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base Distribution and Headquarters
  • Table 24. Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Offered
  • Table 25. Date of Manufacturers Enter into Myelodysplastic Syndrome (MDS) Treatment Market
  • Table 26. Mergers & Acquisitions, Expansion Plans
  • Table 27. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 28. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 29. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Type (2017-2022)
  • Table 30. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Type (2023-2028)
  • Table 31. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 32. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 33. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Type (2017-2022)
  • Table 34. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Type (2023-2028)
  • Table 35. Myelodysplastic Syndrome (MDS) Treatment Price by Type (2017-2022) & (USD/Unit)
  • Table 36. Global Myelodysplastic Syndrome (MDS) Treatment Price Forecast by Type (2023-2028) & (USD/Unit)
  • Table 37. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 38. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 39. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Application (2017-2022)
  • Table 40. Global Myelodysplastic Syndrome (MDS) Treatment Sales Share by Application (2023-2028)
  • Table 41. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 42. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 43. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Application (2017-2022)
  • Table 44. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Application (2023-2028)
  • Table 45. Myelodysplastic Syndrome (MDS) Treatment Price by Application (2017-2022) & (USD/Unit)
  • Table 46. Global Myelodysplastic Syndrome (MDS) Treatment Price Forecast by Application (2023-2028) & (USD/Unit)
  • Table 47. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 48. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 49. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 50. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 51. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 52. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 53. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 54. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 55. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2022) & (K Units)
  • Table 56. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2023-2028) & (K Units)
  • Table 57. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2022) & (US$ Million)
  • Table 58. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2023-2028) & (US$ Million)
  • Table 59. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 60. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 61. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 62. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 63. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 64. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 65. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 66. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 67. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2022) & (K Units)
  • Table 68. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2023-2028) & (K Units)
  • Table 69. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2022) & (US$ Million)
  • Table 70. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2023-2028) & (US$ Million)
  • Table 71. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 72. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 73. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 74. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 75. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 76. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 77. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 78. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 79. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2017-2022) & (K Units)
  • Table 80. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2023-2028) & (K Units)
  • Table 81. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2017-2022) & (US$ Million)
  • Table 82. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2023-2028) & (US$ Million)
  • Table 83. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 84. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 85. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 86. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 87. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 88. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 89. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 90. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 91. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2022) & (K Units)
  • Table 92. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2023-2028) & (K Units)
  • Table 93. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2022) & (US$ Million)
  • Table 94. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2023-2028) & (US$ Million)
  • Table 95. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2022) & (K Units)
  • Table 96. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2023-2028) & (K Units)
  • Table 97. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2022) & (US$ Million)
  • Table 98. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2023-2028) & (US$ Million)
  • Table 99. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2022) & (K Units)
  • Table 100. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2023-2028) & (K Units)
  • Table 101. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2022) & (US$ Million)
  • Table 102. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2023-2028) & (US$ Million)
  • Table 103. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2022) & (K Units)
  • Table 104. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2023-2028) & (K Units)
  • Table 105. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2022) & (US$ Million)
  • Table 106. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2023-2028) & (US$ Million)
  • Table 107. Novartis AG Corporation Information
  • Table 108. Novartis AG Description and Major Businesses
  • Table 109. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 110. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 111. Novartis AG Recent Developments
  • Table 112. Celgene Corporation Corporation Information
  • Table 113. Celgene Corporation Description and Major Businesses
  • Table 114. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 115. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 116. Celgene Corporation Recent Developments
  • Table 117. Otsuka Pharmaceutical Co., Ltd Corporation Information
  • Table 118. Otsuka Pharmaceutical Co., Ltd Description and Major Businesses
  • Table 119. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 120. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 121. Otsuka Pharmaceutical Co., Ltd Recent Developments
  • Table 122. Sandoz Inc Corporation Information
  • Table 123. Sandoz Inc Description and Major Businesses
  • Table 124. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 125. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 126. Sandoz Inc Recent Developments
  • Table 127. Dr Reddys Laboratories Limited Corporation Information
  • Table 128. Dr Reddys Laboratories Limited Description and Major Businesses
  • Table 129. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 130. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 131. Dr Reddys Laboratories Limited Recent Developments
  • Table 132. Pharmascience Inc Corporation Information
  • Table 133. Pharmascience Inc Description and Major Businesses
  • Table 134. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 135. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 136. Pharmascience Inc Recent Developments
  • Table 137. Accord Healthcare Ltd Corporation Information
  • Table 138. Accord Healthcare Ltd Description and Major Businesses
  • Table 139. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 140. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 141. Accord Healthcare Ltd Recent Developments
  • Table 142. Mylan N.V. Corporation Information
  • Table 143. Mylan N.V. Description and Major Businesses
  • Table 144. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 145. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 146. Mylan N.V. Recent Developments
  • Table 147. Key Raw Materials Lists
  • Table 148. Raw Materials Key Suppliers Lists
  • Table 149. Myelodysplastic Syndrome (MDS) Treatment Distributors List
  • Table 150. Myelodysplastic Syndrome (MDS) Treatment Customers List
  • Table 151. Myelodysplastic Syndrome (MDS) Treatment Market Trends
  • Table 152. Myelodysplastic Syndrome (MDS) Treatment Market Drivers
  • Table 153. Myelodysplastic Syndrome (MDS) Treatment Market Challenges
  • Table 154. Myelodysplastic Syndrome (MDS) Treatment Market Restraints
  • Table 155. Research Programs/Design for This Report
  • Table 156. Key Data Information from Secondary Sources
  • Table 157. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Myelodysplastic Syndrome (MDS) Treatment Product Picture
  • Figure 3. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Type in 2021 & 2028
  • Figure 3. Azacitidine Product Picture
  • Figure 4. Lenalidomide Product Picture
  • Figure 5. Decitabine Product Picture
  • Figure 6. Deferasirox Product Picture
  • Figure 7. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Application in 2021 & 2028
  • Figure 8. Refractory Cytopenia with Unilineage Dysplasia
  • Figure 9. Refractory Anemia with Ringed Sideroblasts
  • Figure 10. Others
  • Figure 11. Myelodysplastic Syndrome (MDS) Treatment Report Years Considered
  • Figure 12. Global Myelodysplastic Syndrome (MDS) Treatment Sales 2017-2028 (K Units)
  • Figure 13. Global Myelodysplastic Syndrome (MDS) Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 14. Global Myelodysplastic Syndrome (MDS) Treatment Revenue 2017-2028 (US$ Million)
  • Figure 15. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 16. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2017-2022)
  • Figure 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2023-2028)
  • Figure 18. North America Myelodysplastic Syndrome (MDS) Treatment Sales YoY (2017-2028) & (K Units)
  • Figure 19. North America Myelodysplastic Syndrome (MDS) Treatment Revenue YoY (2017-2028) & (US$ Million)
  • Figure 20. Europe Myelodysplastic Syndrome (MDS) Treatment Sales YoY (2017-2028) & (K Units)
  • Figure 21. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue YoY (2017-2028) & (US$ Million)
  • Figure 22. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales YoY (2017-2028) & (K Units)
  • Figure 23. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue YoY (2017-2028) & (US$ Million)
  • Figure 24. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales YoY (2017-2028) & (K Units)
  • Figure 25. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue YoY (2017-2028) & (US$ Million)
  • Figure 26. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales YoY (2017-2028) & (K Units)
  • Figure 27. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue YoY (2017-2028) & (US$ Million)
  • Figure 28. The Myelodysplastic Syndrome (MDS) Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 29. The Top 5 and 10 Largest Manufacturers of Myelodysplastic Syndrome (MDS) Treatment in the World: Market Share by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2021
  • Figure 30. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 31. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 32. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 33. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 34. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 35. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 36. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 37. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 38. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 39. North America Myelodysplastic Syndrome (MDS) Treatment Sales Share by Country (2017-2028)
  • Figure 40. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Country (2017-2028)
  • Figure 41. U.S. Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 42. Canada Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 43. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 44. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 45. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 46. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 47. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Share by Country (2017-2028)
  • Figure 48. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Country (2017-2028)
  • Figure 49. Germany Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 50. France Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 51. U.K. Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 52. Italy Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 53. Russia Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 54. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 55. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 56. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 57. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 58. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Share by Region (2017-2028)
  • Figure 59. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Region (2017-2028)
  • Figure 60. China Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 61. Japan Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 62. South Korea Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 63. India Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 64. Australia Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 65. Taiwan Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 66. Indonesia Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 67. Thailand Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 68. Malaysia Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 69. Philippines Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 70. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 71. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 72. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 73. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 74. Latin America Myelodysplastic Syndrome (MDS) Treatment Sales Share by Country (2017-2028)
  • Figure 75. Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Country (2017-2028)
  • Figure 76. Mexico Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 77. Brazil Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 78. Argentina Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 79. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • Figure 80. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • Figure 81. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • Figure 82. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • Figure 83. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales Share by Country (2017-2028)
  • Figure 84. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Country (2017-2028)
  • Figure 85. Turkey Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 86. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 87. U.A.E Myelodysplastic Syndrome (MDS) Treatment Revenue (2017-2028) & (US$ Million)
  • Figure 88. Myelodysplastic Syndrome (MDS) Treatment Value Chain
  • Figure 89. Myelodysplastic Syndrome (MDS) Treatment Production Process
  • Figure 90. Channels of Distribution
  • Figure 91. Distributors Profiles
  • Figure 92. Bottom-up and Top-down Approaches for This Report
  • Figure 93. Data Triangulation
  • Figure 94. Key Executives Interviewed
目次

This research report focuses on the Myelodysplastic Syndrome (MDS) Treatment Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Azacitidine
    • 1.2.3 Lenalidomide
    • 1.2.4 Decitabine
    • 1.2.5 Deferasirox
  • 1.3 Market by Application
    • 1.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Refractory Cytopenia with Unilineage Dysplasia
    • 1.3.3 Refractory Anemia with Ringed Sideroblasts
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Estimates and Forecasts 2017-2028
  • 2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region
    • 2.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2017-2022)
    • 2.4.2 Global Sales Myelodysplastic Syndrome (MDS) Treatment by Region (2023-2028)
  • 2.5 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region
    • 2.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2017-2022)
    • 2.5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
    • 3.1.1 Global Top Myelodysplastic Syndrome (MDS) Treatment Manufacturers by Sales (2017-2022)
    • 3.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Myelodysplastic Syndrome (MDS) Treatment in 2021
  • 3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers
    • 3.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2021
  • 3.3 Global Myelodysplastic Syndrome (MDS) Treatment Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Myelodysplastic Syndrome (MDS) Treatment Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type
    • 4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Historical Sales by Type (2017-2022)
    • 4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2017-2028)
  • 4.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type
    • 4.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Historical Revenue by Type (2017-2022)
    • 4.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2017-2028)
  • 4.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Type
    • 4.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2017-2022)
    • 4.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application
    • 5.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Historical Sales by Application (2017-2022)
    • 5.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2017-2028)
  • 5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application
    • 5.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Historical Revenue by Application (2017-2022)
    • 5.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2017-2028)
  • 5.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Application
    • 5.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2017-2022)
    • 5.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Type
    • 6.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2028)
    • 6.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2028)
  • 6.2 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Application
    • 6.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2028)
    • 6.2.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2028)
  • 6.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
    • 6.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2028)
    • 6.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2028)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Type
    • 7.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2028)
    • 7.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2028)
  • 7.2 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Application
    • 7.2.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2028)
    • 7.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2028)
  • 7.3 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
    • 7.3.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2028)
    • 7.3.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Type
    • 8.1.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Application
    • 8.2.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region
    • 8.3.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Type
    • 9.1.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2028)
    • 9.1.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2028)
  • 9.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Application
    • 9.2.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2028)
    • 9.2.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2028)
  • 9.3 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
    • 9.3.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2028)
    • 9.3.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Type
    • 10.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Application
    • 10.2.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
    • 10.3.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 Novartis AG
    • 11.1.1 Novartis AG Corporation Information
    • 11.1.2 Novartis AG Overview
    • 11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Novartis AG Recent Developments
  • 11.2 Celgene Corporation
    • 11.2.1 Celgene Corporation Corporation Information
    • 11.2.2 Celgene Corporation Overview
    • 11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Celgene Corporation Recent Developments
  • 11.3 Otsuka Pharmaceutical Co., Ltd
    • 11.3.1 Otsuka Pharmaceutical Co., Ltd Corporation Information
    • 11.3.2 Otsuka Pharmaceutical Co., Ltd Overview
    • 11.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
  • 11.4 Sandoz Inc
    • 11.4.1 Sandoz Inc Corporation Information
    • 11.4.2 Sandoz Inc Overview
    • 11.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Sandoz Inc Recent Developments
  • 11.5 Dr Reddys Laboratories Limited
    • 11.5.1 Dr Reddys Laboratories Limited Corporation Information
    • 11.5.2 Dr Reddys Laboratories Limited Overview
    • 11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Dr Reddys Laboratories Limited Recent Developments
  • 11.6 Pharmascience Inc
    • 11.6.1 Pharmascience Inc Corporation Information
    • 11.6.2 Pharmascience Inc Overview
    • 11.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Pharmascience Inc Recent Developments
  • 11.7 Accord Healthcare Ltd
    • 11.7.1 Accord Healthcare Ltd Corporation Information
    • 11.7.2 Accord Healthcare Ltd Overview
    • 11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Accord Healthcare Ltd Recent Developments
  • 11.8 Mylan N.V.
    • 11.8.1 Mylan N.V. Corporation Information
    • 11.8.2 Mylan N.V. Overview
    • 11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Mylan N.V. Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Myelodysplastic Syndrome (MDS) Treatment Industry Chain Analysis
  • 12.2 Myelodysplastic Syndrome (MDS) Treatment Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Myelodysplastic Syndrome (MDS) Treatment Production Mode & Process
  • 12.4 Myelodysplastic Syndrome (MDS) Treatment Sales and Marketing
    • 12.4.1 Myelodysplastic Syndrome (MDS) Treatment Sales Channels
    • 12.4.2 Myelodysplastic Syndrome (MDS) Treatment Distributors
  • 12.5 Myelodysplastic Syndrome (MDS) Treatment Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Myelodysplastic Syndrome (MDS) Treatment Industry Trends
  • 13.2 Myelodysplastic Syndrome (MDS) Treatment Market Drivers
  • 13.3 Myelodysplastic Syndrome (MDS) Treatment Market Challenges
  • 13.4 Myelodysplastic Syndrome (MDS) Treatment Market Restraints

14 Key Findings in The Global Myelodysplastic Syndrome (MDS) Treatment Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer